Peer-influenced content. Sources you trust. No registration required. This is HCN.
Huntington’s Disease News
The first participant was dosed in a Phase 3 trial of oral votoplam, as interim Phase 2 extension data suggested dose-dependent slowing of Huntington’s progression.
Neurology May 28th 2026